维奈克拉方案治疗复发难治性t(11;14)多发性骨髓瘤的真实世界数据
总缓解率为78%,其中1例合并心脏淀粉样变性的患者获得心脏器官缓解。观察到需输注红细胞和血小板的血液学毒性及以胃肠道反应最常见的非血液学毒性。
要点
- 维奈克拉方案在t(11;14) RRMM中总缓解率达78%。
- 需关注血液学毒性(贫血、血小板减少)及胃肠道反应。
- 合并心脏淀粉样变性患者可获器官缓解。
核心结论
- 维奈克拉方案在RRMM患者中显示出有希望的疗效,总缓解率为78%。
主要发现
- 总缓解率为78%。
- 1例合并心脏淀粉样变性和MM的患者获得心脏器官缓解。
- 观察到需红细胞和血小板输注的血液学毒性。
- 非血液学毒性最常见为胃肠道不适。
临床怎么用
- 维奈克拉方案可用于t(11;14) RRMM患者,治疗中需监测血液学毒性及胃肠道反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment for relapsed/refractory multiple myeloma (RRMM) continues to be challenging despite recent therapeutic advancements. Venetoclax, an inhibitor of the anti-apoptotic protein BCL-2, is a promising agent, especially in patients harbouring t(11;14). Our objective was to review our experience with venetoclax-based regimens at our institution. All ten RRMM patients treated with venetoclax were included and had a median of six prior lines of therapy. The overall response rate was 78% and one patient with cardiac amyloidosis and MM achieved a cardiac organ response. Haematologic toxicities requiring red blood cell and platelet transfusion and non-haematologic toxicities, most commonly gastrointestinal upset, were observed.
引用
- Basali D, Chakraborty R, Rybicki L, et al. Real-world data on safety and efficacy of venetoclax-based regimens in relapsed/refractory t(11;14) multiple myeloma. Br J Haematol. 2020. PMID: 32012228. doi:10.1111/bjh.16454
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。